Stock Events

Stock Events

PhaseBio Pharmaceuticals 

$0.07
10
-$0.02-26.21% Wednesday 21:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q4 2021
Q1 2022
Q2 2022
Q4 2022
Q1 2024
Q2 2024
Q3 2024
-0.9
-0.68
-0.45
-0.23
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,210.15%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
10,831Revenue
-131,071Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHAS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology company that develops and manufactures innovative human therapeutics, including treatments for cardiovascular diseases, which competes with PhaseBio's focus on cardiopulmonary disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on developing medications for serious medical conditions, including cardiovascular diseases, directly competing with PhaseBio's product pipeline.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a global healthcare company with a strong focus on diabetes and obesity management, but also on hemostasis management, which overlaps with PhaseBio's interest in bleeding disorders.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including areas like cardiovascular health, competing with PhaseBio's therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad range of products in various therapeutic areas, including cardiovascular diseases, making it a competitor to PhaseBio.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in several therapeutic areas, including cardiovascular, renal, and metabolism, directly competing with PhaseBio's focus areas.
Merck
MRK
Mkt Cap214.76B
Merck is known for its contributions to healthcare, including cardiovascular disease treatments, positioning it as a competitor to PhaseBio.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on a broad spectrum of therapeutic areas, including cardiovascular diseases, which makes it a direct competitor to PhaseBio.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals companies, develops treatments for a wide range of health conditions, including cardiovascular diseases, competing with PhaseBio.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a diverse line of therapies, including interest in cardiovascular diseases, making it a competitor to PhaseBio in the pharmaceutical landscape.

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
Show more...
CEO
Jonathan Mow
Employees
60
Country
US
ISIN
US7172241090
WKN
000A2N7LU

Listings

0 Comments

Share your thoughts

FAQ

What is PhaseBio Pharmaceuticals stock price today?▼
The current price of PHAS is $0.07 USD — it has decreased by -26.21% in the past 24 hours. Watch PhaseBio Pharmaceuticals stock price performance more closely on the chart.
What is PhaseBio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PhaseBio Pharmaceuticals stocks are traded under the ticker PHAS.
What is PhaseBio Pharmaceuticals revenue for the last year?▼
PhaseBio Pharmaceuticals revenue for the last year amounts to 10,831 USD.
What is PhaseBio Pharmaceuticals net income for the last year?▼
PHAS net income for the last year is -131,071 USD.
How many employees does PhaseBio Pharmaceuticals have?▼
As of April 01, 2026, the company has 60 employees.
In which sector is PhaseBio Pharmaceuticals located?▼
PhaseBio Pharmaceuticals operates in the Manufacturing sector.
When did PhaseBio Pharmaceuticals complete a stock split?▼
PhaseBio Pharmaceuticals has not had any recent stock splits.
Where is PhaseBio Pharmaceuticals headquartered?▼
PhaseBio Pharmaceuticals is headquartered in Malvern, US.